Roivant Sciences Ltd. (ROIV)
NASDAQ
Healthcare
Biotechnology
$29.05
▲ +1.97%
Market Cap
$20.89B
Sector
Healthcare
Industry
Biotechnology
Beta
1.14
52-Wk Range
10.705-32.793
CEO
Matthew Gline
Country
GB
Currency
USD
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myastheni…
Open full interactive analysis & DCF →